PI3Kα Allosteric Inhibitors for Selective Cancer Kinase Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kinase inhibitors targeting the ATP binding site lack selectivity, leading to off-target binding, toxicity, and resistance due to mutations, necessitating the development of allosteric inhibitors that specifically target PI3Kα.
Innovation Solution
Development of PI3Kα inhibitors that form direct binding interactions with an allosteric pocket on PI3Kα, comprising specific amino acids like Thr813, Leu911, and Phe1002, with a binding affinity of 0.1 nM to 1 μM, stabilizing the activation loop in a catalytically incompetent conformation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If kinase inhibitors target the ATP binding site, then they can inhibit kinase activity, but they lack selectivity between different kinases leading to off-target binding and toxicity
Solution Approach 1:
The patent extracts the inhibitor binding site from the conserved ATP binding pocket to a unique allosteric pocket located at the interface between the catalytic and regulatory subunits. This allosteric pocket contains specific amino acid residues (Thr813, Leu911, Phe1002) that are not present in the ATP binding site, allowing the inhibitor to bind selectively to PI3Kα without affecting other kinases that share the ATP binding site structure.
Solution Approach 2:
The patent creates local quality differences by targeting a specific structural feature (the allosteric pocket formed by the p110α catalytic subunit and p85α regulatory subunit interface) that is unique to PI3Kα. The inhibitor is designed to interact with specific local residues (Thr813, Leu911, Phe1002) rather than the general ATP binding site, providing selectivity while maintaining inhibition efficacy.
2Reliability
If kinase inhibitors target the ATP binding site, then they can compete with ATP binding, but they require highly potent compounds to compete with millimolar intracellular ATP concentrations
Solution Approach 1:
The patent introduces an allosteric binding site as an intermediary target that does not directly compete with ATP for the same binding pocket. The inhibitor binds to a distinct allosteric pocket formed by the interface between catalytic and regulatory subunits, allowing it to modulate kinase activity through conformational changes rather than direct ATP competition, thereby reducing the required potency.
3Reliability
If kinase inhibitors target the ATP binding site, then they can inhibit kinase activity, but mutations in and around the ATP pocket can confer resistance
Solution Approach 1:
The patent targets a unique local structure (the allosteric pocket with specific residues Thr813, Leu911, Phe1002) that is not part of the conserved ATP binding site. Mutations in common ATP pocket residues (like gatekeeper residues) do not affect binding to this distinct allosteric site, thereby preventing the development of resistance through typical mutation pathways.
4Object-affected harmful factors
If allosteric inhibitors are developed to improve selectivity, then off-target binding is reduced, but the allosteric pocket must be revealed by displacing Phe937 and Leu938
Solution Approach 1:
The patent employs a dynamic binding mechanism where the inhibitor induces conformational changes in the PI3Kα structure. Specifically, binding to the allosteric pocket causes displacement of Phe937 and Leu938, which reveals or stabilizes the allosteric pocket structure. This dynamic structural adaptation allows selective binding while maintaining a relatively simple inhibitor design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PI3Kα inhibitors effectively inhibit PI3K activity with high specificity and reduced toxicity, offering a potential therapeutic approach for cancer treatment by disrupting the PI3K/AKT signaling pathway.
Implementation Method 1
the compound forms direct binding interactions with one or more amino acids of the allosteric pocket
Implementation Method 2
a first, a second, and a third hydrogen bonding moiety each capable of forming hydrogen bonds with Leu911 and/or Lys941 of PI3KαH1047R
Implementation Method 3
the first and second aromatic moieties are each capable of forming a pi-pi stacking interaction with Phe937 of PI3KαH1047R
Implementation Method 4
a hydrophobic moiety about 2.5 Å from the third hydrogen bonding moiety and is capable of interacting with Ile1022 of PI3KαH1047R
Implementation Method 5
an allosteric pocket on PI3Kα revealed by displacing Phe937 and Leu938, thereby exposing the allosteric pocket
Data Source
AI summary
This disclosure provides compounds and pharmaceutically acceptable salts thereof that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα), as well as methods of screening for such compounds.